SLRN
Price:
$4.7
Market Cap:
$469.10M
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatm...[Read more]
Industry
Biotechnology
IPO Date
2023-05-04
Stock Exchange
NASDAQ
Ticker
SLRN
According to Acelyrin, Inc.’s latest financial reports and current stock price. The company's current ROE is -44.12%. This represents a change of 299.28% compared to the average of -11.05% of the last 4 quarters.
The mean historical ROE of Acelyrin, Inc. over the last ten years is 88.73%. The current -44.12% ROE has changed -149.73% with respect to the historical average. Over the past ten years (40 quarters), SLRN's ROE was at its highest in in the December 2022 quarter at 184.48%. The ROE was at its lowest in in the March 2022 quarter at -17.76%.
Average
88.73%
Median
99.48%
Minimum
-58.15%
Maximum
224.85%
Discovering the peaks and valleys of Acelyrin, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 126.01%
Maximum Annual ROE = 224.85%
Minimum Annual Increase = -125.86%
Minimum Annual ROE = -58.15%
Year | ROE | Change |
---|---|---|
2023 | -58.15% | -125.86% |
2022 | 224.85% | 126.01% |
The current ROE of Acelyrin, Inc. (SLRN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
88.73%
5-year avg
88.73%
10-year avg
88.73%
Acelyrin, Inc.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Acelyrin, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Acelyrin, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Acelyrin, Inc.'s ROE?
How is the ROE calculated for Acelyrin, Inc. (SLRN)?
What is the highest ROE for Acelyrin, Inc. (SLRN)?
What is the 3-year average ROE for Acelyrin, Inc. (SLRN)?
What is the 5-year average ROE for Acelyrin, Inc. (SLRN)?
How does the current ROE for Acelyrin, Inc. (SLRN) compare to its historical average?